CAS: 14923-84-3; Pyrene-1,6-Diamine

相似化合物

1606-67-3 5522-43-0 30269-04-6

上下游产品

CAS号42397-64-8 1,6-二硝基芘 | CAS号129-00-0 芘 | CAS号30269-01-3 6-nitropyren-1-amine | CAS号5522-43-0 1-硝基芘 | CAS号42397-65-9 1,8-二硝基芘 | CAS号42397-64-8 1,6-二硝基芘 | CAS号75321-20-9 1,3-二硝基芘 | CAS号10075-93-1 1-N,1-N,6-N,6-N... | CAS号1785-51-9 1,6-Pyrenedione

📜芘置于硝酸,溶剂黄146,Palladium 10% On Activated Carbon,氢气体系中,用 乙醇 用作溶剂,化学反应 24.5H,以820 Mg的收率获得1,6-二氨基芘
参考文献:Diaminopyrene Modified Reduced Graphene Oxide As A Novel Electrode Material For Excellent Performance Supercapacitors
标题:Diaminopyrene Modified Reduced Graphene Oxide As A Novel Electrode Material For Excellent Performance Supercapacitors
摘要:Daprgos纳米复合材料的简易合成过程示意图,Ragone图和组装的daprgo1//daprgo1 Sss的优越循环稳定性.
Doi:10.1039/c9Ra10429A

专利信息

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.